{
    "nctId": "NCT03750396",
    "briefTitle": "Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer",
    "officialTitle": "Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor, Her2-negative Tumor, Surgery",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n-ER-positive/HER2-negative in primary tumor\n\n* Oligometastases: \u2264 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)\n* Recurrent cancer after completion of primary treatment (RFI\u22651year)\n* Metastatic lesions are feasible for resection or radiotherapy (Size\u22643cm)\n\nExclusion Criteria:\n\n* De Novo metastatic cancer at initial diganosis\n* Recurrence-free inverval \\< 1 year",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}